We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Faron Pharmaceuticals Oy | LSE:FARN | London | Ordinary Share | FI4000153309 | ORD NPV (DI) |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 150.00 | 140.00 | 160.00 | 150.00 | 150.00 | 150.00 | 4,213 | 07:44:03 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Pharmaceutical Preparations | 0 | -28.73M | -0.4177 | -3.59 | 103.18M |
TIDMFARN
RNS Number : 4814P
Faron Pharmaceuticals Oy
17 February 2021
Faron Pharmaceuticals Oy
("Faron" or the "Company")
Holding(s) in the Company
Company announcement, 17 February 2021 at 4.30pm GMT / 6.30pm EET
TURKU - FINLAND - Faron Pharmaceuticals Oy (First North: FARON, AIM: FARN), the clinical stage biopharmaceutical company, has on 16 February 2021 received notifications from Mr. Timo Syrjälä and Mr. Tom-Erik Lind of the decrease of their holdings due to issuance of new shares.
Trading in the Placing Shares commenced on First North and AIM on 16 February 2021.
The mentioned notifications are attached in this announcement.
For more information please contact:
Faron Pharmaceuticals Oy
Dr Markku Jalkanen, Chief Executive Officer
investor.relations@faron.com
Cairn Financial Advisers LLP, Nomad
Sandy Jamieson, Jo Turner, Mark Rogers
Phone: + 44 207 213 0880
Sisu Partners Oy, Certified Adviser on Nasdaq First North
Juha Karttunen
Phone: +358 40 555 4727
Jukka Järvelä
Phone: +358 50 553 8990
Consilium Strategic Communications
Mary-Jane Elliott, David Daley, Lindsey Neville
Phone: +44 (0)20 3709 5700
E-mail: faron@consilium-comms.com
Stern Investor Relations
Julie Seidel, Naina Zaman
Phone: +1 (212) 362-1200
E-mail: julie.seidel@sternir.com
About Faron Pharmaceuticals Ltd
Faron (AIM: FARN, First North: FARON) is a clinical stage biopharmaceutical company developing novel treatments for medical conditions with significant unmet needs. The Company currently has a pipeline based on the receptors involved in regulation of immune response in oncology and organ damage. Bexmarilimab is its investigative precision immunotherapy with the potential to provide permanent immune stimulation for difficult-to-treat cancers through targeting myeloid function. A novel anti-Clever-1 humanised antibody, bexmarilimab targets Clever-1 positive (Common Lymphatic Endothelial and Vascular Endothelial Receptor 1) tumour associated macrophages (TAMs) in the tumour microenvironment, converting these highly immunosuppressive M2 macrophages to immune stimulating M1 macrophages. With the ability to switch immune suppression to immune activation in various conditions, bexmarilimab has potential across oncology, infectious diseases and vaccine development. Currently in phase I/II clinical development as a potential therapy for patients with untreatable solid tumours, bexmarilimab has potential as a single-agent therapy or in combination with other standard treatments including immune checkpoint molecules. Traumakine is an investigational intravenous (IV) interferon beta-1a therapy for the treatment of acute respiratory distress syndrome (ARDS) and other ischemic or hyperinflammatory conditions. In addition to its profound antiviral effect, Traumakine upregulates the cell surface protein Cluster of Differentiation 73 (CD73), an enzyme that suppresses pro-inflammatory responses in endothelial cells. Using an IV administration of interferon beta-1a provides optimal exposure to the lung vasculature, increasing protection against serious lung complications and helping to prevent vascular leakage by enhancing endothelial barrier function. Traumakine is currently being evaluated in global trials as a potential treatment for hospitalised patients with COVID-19. As part of a working relationship established with Faron, the 59th Medical Wing of the US Air Force and the US Department of Defense are also evaluating Traumakine's role in preventing multiple organ dysfunction syndrome (MODS) after ischemia-reperfusion injury caused by a major trauma. Faron is based in Turku, Finland. Further information is available at www.faron.com .
TR-1: Standard form for notification of major holdings
NOTIFICATION OF MAJOR HOLDINGS (to be sent to the relevant issuer and to the FCA in Microsoft Word format if possible) (i) 1a. Identity of the issuer or the Faron Pharmaceuticals Ltd underlying issuer of existing shares to which voting rights are attached (ii) : ------------------------------------------- 1b. Please indicate if the issuer is a non-UK issuer (please mark with an "X" if appropriate) Non-UK issuer X ----- 2. Reason for the notification (please mark the appropriate box or boxes with an "X") An acquisition or disposal of voting rights ----- An acquisition or disposal of financial instruments ----- An event changing the breakdown of voting rights ----- Other (please specify)(iii) : (Decrease of holding due to issuance X of new shares) ----- 3. Details of person subject to the notification obligation (iv) Name Timo Syrjälä City and country of registered office (if applicable) 4. Full name of shareholder(s) (if different from 3.) (v) Name ------------------------------------------- City and country of registered office (if applicable) ------------------------------------------- 5. Date on which the threshold was 12.2.2021 crossed or reached (vi) : ------------------------------------------- 6. Date on which issuer notified (DD/MM/YYYY): 16.2.2021 ------------------------------------------- 7. Total positions of person(s) subject to the notification obligation % of voting % of voting rights Total of both Total number rights attached through financial in % (8.A + of voting rights to shares (total instruments 8.B) of issuer (vii) of 8. A) (total of 8.B 1 + 8.B 2) ------------------ --------------------- -------------- -------------------- Resulting situation on the date on which threshold was crossed or reached 13.57 13.57 50,417,874 ------------------ --------------------- -------------- -------------------- Position of previous notification (if applicable) 14.08% 14.08% ------------------ --------------------- -------------- -------------------- 8. Notified details of the resulting situation on the date on which the threshold was crossed or reached (viii) A: Voting rights attached to shares Class/type of Number of voting rights % of voting rights shares (ix) ISIN code (if possible) -------------------------------------------------- Direct Indirect Direct Indirect (Art 9 of Directive (Art 10 of Directive (Art 9 of Directive (Art 10 of Directive 2004/109/EC) 2004/109/EC) 2004/109/EC) (DTR5.1) 2004/109/EC) (DTR5.1) (DTR5.2.1) (DTR5.2.1) ---------------------- -------------------------- ------------------------- --------------------- FI4000153309 2,561,402 4,277,837 5.08% 8.48% ---------------------- -------------------------- ------------------------- --------------------- SUBTOTAL 8. A 6,839,239 13.57% -------------------------------------------------- ------------------------------------------------ B 1: Financial Instruments according to Art. 13(1)(a) of Directive 2004/109/EC (DTR5.3.1.1 (a)) Type of Expiration Exercise/ Number of voting % of voting rights financial date Conversion Period rights that may instrument (x) (xi) be acquired if the instrument is exercised/converted. ----------- ------------------------------ -------------------------------- --------------------- SUBTOTAL 8. B 1 ------------------------------ -------------------------------- --------------------- B 2: Financial Instruments with similar economic effect according to Art. 13(1)(b) of Directive 2004/109/EC (DTR5.3.1.1 (b)) Type of Expiration Exercise/ Physical or Number of % of voting rights financial date (x) Conversion cash voting rights
instrument Period (xi) settlement (xii) ---------------- -------------------- -------------------- -------------------- SUBTOTAL 8.B.2 -------------------- -------------------- 9. Information in relation to the person subject to the notification obligation (please mark the applicable box with an "X") Person subject to the notification obligation is not controlled by any natural person or legal entity and does not control any other undertaking(s) holding directly or indirectly an interest in the (underlying) issuer(xiii) Full chain of controlled undertakings through which the voting rights X and/or the financial instruments are effectively held starting with the ultimate controlling natural person or legal entity(xiv) (please add additional rows as necessary) Name (xv) % of voting rights % of voting rights Total of both if if it equals or through financial it equals or is higher is higher than the instruments if it than the notifiable notifiable threshold equals or is higher threshold than the notifiable threshold ---------------------- --------------------- -------------------------- Timo Syrjälä (Direct) 5.08% 5.08% ---------------------- --------------------- -------------------------- Acme Investments SPF Sarl (Indirect) 8.48% 8.48% ---------------------- --------------------- -------------------------- 10. In case of proxy voting, please identify: Name of the proxy holder ------------------------------------------------- The number and % of voting rights held ------------------------------------------------- The date until which the voting rights will be held ------------------------------------------------- 11. Additional information (xvi) Decrease due to issuance of shares Place of completion Luxembourg Date of completion 16.02.2021 -----------
TR-1: Standard form for notification of major holdings
NOTIFICATION OF MAJOR HOLDINGS (to be sent to the relevant issuer and to the FCA in Microsoft Word format if possible) (i) 1a. Identity of the issuer or the Faron Pharmaceuticals Ltd underlying issuer of existing shares to which voting rights are attached (ii) : ------------------------------------------- 1b. Please indicate if the issuer is a non-UK issuer (please mark with an "X" if appropriate) Non-UK issuer X ----- 2. Reason for the notification (please mark the appropriate box or boxes with an "X") An acquisition or disposal of voting rights ----- An acquisition or disposal of financial instruments ----- An event changing the breakdown of voting rights ----- Other (please specify)(iii) : (Decrease of holding due to issuance x of new shares) ----- 3. Details of person subject to the notification obligation (iv) Name Tom-Erik Lind City and country of registered office (if applicable) 4. Full name of shareholder(s) (if different from 3.) (v) Name ------------------------------------------- City and country of registered office (if applicable) ------------------------------------------- 5. Date on which the threshold was 12.2.2021 crossed or reached (vi) : ------------------------------------------- 6. Date on which issuer notified (DD/MM/YYYY): 16.2.2021 ------------------------------------------- 7. Total positions of person(s) subject to the notification obligation % of voting % of voting rights Total of both Total number rights attached through financial in % (8.A + of voting rights to shares (total instruments 8.B) of issuer (vii) of 8. A) (total of 8.B 1 + 8.B 2) ------------------ --------------------- -------------- -------------------- Resulting situation on the date on which threshold was crossed or reached 7.55 7.55 50,417,874 ------------------ --------------------- -------------- -------------------- Position of previous notification (if applicable) 10.00% 10.00% ------------------ --------------------- -------------- -------------------- 8. Notified details of the resulting situation on the date on which the threshold was crossed or reached (viii) A: Voting rights attached to shares Class/type of Number of voting rights % of voting rights shares (ix) ISIN code (if possible) -------------------------------------------------- Direct Indirect Direct Indirect (Art 9 of Directive (Art 10 of Directive (Art 9 of Directive (Art 10 of Directive 2004/109/EC) 2004/109/EC) 2004/109/EC) (DTR5.1) 2004/109/EC) (DTR5.1) (DTR5.2.1) (DTR5.2.1) ---------------------- -------------------------- ------------------------- --------------------- FI4000153309 3,806,611 7.55 ---------------------- -------------------------- ------------------------- --------------------- SUBTOTAL 8. A 3,806,611 7.55% -------------------------------------------------- ------------------------------------------------ B 1: Financial Instruments according to Art. 13(1)(a) of Directive 2004/109/EC (DTR5.3.1.1 (a)) Type of Expiration Exercise/ Number of voting % of voting rights financial date Conversion Period rights that may instrument (x) (xi) be acquired if the instrument is exercised/converted. ----------- ------------------------------ -------------------------------- --------------------- SUBTOTAL 8. B 1 ------------------------------ -------------------------------- --------------------- B 2: Financial Instruments with similar economic effect according to Art. 13(1)(b) of Directive 2004/109/EC (DTR5.3.1.1 (b)) Type of Expiration Exercise/ Physical or Number of % of voting rights financial date (x) Conversion cash voting rights instrument Period (xi) settlement (xii) ---------------- -------------------- -------------------- -------------------- SUBTOTAL 8.B.2 -------------------- -------------------- 9. Information in relation to the person subject to the notification obligation (please mark the applicable box with an "X") Person subject to the notification obligation is not controlled X by any natural person or legal entity and does not control any other undertaking(s) holding directly or indirectly an interest in the (underlying) issuer(xiii) Full chain of controlled undertakings through which the voting rights and/or the financial instruments are effectively held starting with the ultimate controlling natural person or legal entity(xiv) (please add additional rows as necessary)
Name (xv) % of voting rights % of voting rights Total of both if if it equals or through financial it equals or is higher is higher than the instruments if it than the notifiable notifiable threshold equals or is higher threshold than the notifiable threshold ----------------------- --------------------- -------------------------- 10. In case of proxy voting, please identify: Name of the proxy holder ------------------------------------------------- The number and % of voting rights held ------------------------------------------------- The date until which the voting rights will be held ------------------------------------------------- 11. Additional information (xvi) Place of completion Malta Date of completion 16.2.2021 ----------
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
END
HOLZZGMZVNFGMZM
(END) Dow Jones Newswires
February 17, 2021 11:30 ET (16:30 GMT)
1 Year Faron Pharmaceuticals Oy Chart |
1 Month Faron Pharmaceuticals Oy Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions